What is AstraZeneca PLC (AZN.L)'s fair-value range?

EvidInvest does not publish a fair-value range for AstraZeneca PLC (AZN.L). Financials are filed in USD; our prices are in GBp, so these methods need a conversion we do not yet publish. The filed statements, the filing citations and the growth history are all available at https://evidinvest.com/valuation/AZN.L. Not investment advice.

How is AstraZeneca PLC (AZN.L)'s fair value calculated?

AstraZeneca PLC (AZN.L)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples (PE, EV/EBITDA, P/S, P/B) benchmarked against its industry — using data from SEC filings.

What is AstraZeneca PLC (AZN.L)'s PE ratio versus its industry?

EvidInvest shows AstraZeneca PLC (AZN.L)'s current and historical PE ratio alongside its sector and industry averages, so you can see whether the stock trades at a premium or discount to peers. Full breakdown at https://evidinvest.com/valuation/AZN.L.

Fair value · AstraZeneca PLC (AZN.L) · updated 2026-09-13 · from annual report FY2025

AstraZeneca trades at $12,234.00. We are not reading assumptions out of that price: financials are filed in USD; our prices are in GBp, so these methods need a conversion we do not yet publish.

Everything below is unaffected: the filed statements, the filing they came from, and AZN.L’s growth history are all as reported.

Check another stock

The filing behind these numbers

AstraZeneca PLC

Revenue: $58.7B
Diluted EPS: $6.54
Free cash flow: $8.7B; operating cash flow − capital expenditure
Diluted shares: 1.56B; weighted average

annual report FY2025 · fiscal year ended 2025-12-31 · filed 2025-12-31

Trailing-twelve-month EPS also uses the quarterly 6-Ks through Q2 FY2026 (filed 2026-06-30).

Open the annual report list on sec.govCIK 901832

Valuation tool: build your own AZN.L range

Fair Value Summary

Daily Price — AZN.L

$14456.00 +22.6% (1Y)

Your range0 of 7 methods

At least two methods need a usable value to draw a range with these inputs.

Range with preset inputs

No preset range for this company yet.

The two ranges are identical because every input sits on a preset.

We don’t tell you what AZN.L is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has AZN.L’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

N/A

Financials are filed in USD; our prices are in GBp, so these methods need a conversion we do not yet publish.

Preset inputs — revenue-driven DCF from the latest filing

Implied by today’s price

Financials are filed in USD; our prices are in GBp, so these methods need a conversion we do not yet publish.

Not solvable from the price — Financials are filed in USD; our prices are in GBp, so these methods need a conversion we do not yet publish. Showing preset inputs.

This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what AZN.L has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth40.9%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%60.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth9.6%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)5.37%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%15.00%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $321,501M · PV terminal $1,611,755M · EV $1,933,256M · equity $1,909,345M

Year	Stage	FCF	Present value
1	Stage 1	$12,216M	$11,593M
2	Stage 1	$17,212M	$15,503M
3	Stage 1	$24,252M	$20,730M
4	Stage 1	$34,171M	$27,720M
5	Stage 1	$48,148M	$37,067M
6	Stage 2	$52,770M	$38,555M
7	Stage 2	$57,836M	$40,103M
8	Stage 2	$63,388M	$41,713M
9	Stage 2	$69,473M	$43,387M
10	Stage 2	$76,142M	$45,129M

Inputs from the filing

Financials are filed in USD; our prices are in GBp, so these methods need a conversion we do not yet publish.

Free cash flow: $8.4B; sum of the last four quarters
EBIT: $14.1B; latest annual
Shares: 1.55B
Total debt: $29.6B
Cash: $5.7B
Net debt: $23.9B; debt − cash

annual report FY2025 · period ended 2025-12-31 · filed 2025-12-31 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for AZN.L

Loading history...

AstraZeneca trades at $12,234.00. We are not reading assumptions out of that price: financials are filed in USD; our prices are in GBp, so these methods need a conversion we do not yet publish.

The filing behind these numbers

Valuation tool: build your own AZN.L range

Daily Price — AZN.L

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on AZN.L

Compare with peers

Explore

Valuation tool: build your own AZN.L range

Daily Price — AZN.L

Your range0 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on AZN.L

Compare with peers

Explore